Improved Outcomes With Higher Doses of Tisagenlecleucel in Relapsed/Refractory B-ALL
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Blood Advances
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Higher doses of tisagenlecleucel associate with improved outcomes: a report from the pediatric real-world CAR consortium
Blood Adv 2022 Aug 08;[EPub Ahead of Print], H Stefanski, A Eaton, C Baggott, J Rossoff, MR Verneris, AK Keating, S Prabhu, HL Pacenta, CL Phillips, JA Talano, A Moskop, SP Margossian, GD Myers, NA Karras, PA Brown, M Qayed, ML Hermiston, P Satwani, C Krupski, R Wilcox, CA Rabik, VA Fabrizio, V Chinnabhandar, AY Goksenin, E Egeler, S Mavroukakis, KJ Curran, CL Mackall, TW Laetsch, LM SchultzFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.